Shares of Orchard Therapeutics PLC – (NASDAQ:ORTX) have received an average rating of “Buy” from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $26.20.
ORTX has been the subject of a number of research analyst reports. Cowen reissued a “buy” rating and issued a $28.00 price target on shares of Orchard Therapeutics in a report on Monday, December 2nd. ValuEngine raised shares of Orchard Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, February 6th. Finally, Zacks Investment Research downgraded shares of Orchard Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 30th.
Shares of NASDAQ ORTX opened at $12.60 on Friday. Orchard Therapeutics has a twelve month low of $9.78 and a twelve month high of $21.64. The company has a current ratio of 8.88, a quick ratio of 8.88 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -1.23 and a beta of -0.99. The firm has a 50-day moving average of $13.65 and a two-hundred day moving average of $13.10.
In other Orchard Therapeutics news, insider Fmr Llc sold 19,721 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $13.49, for a total transaction of $266,036.29. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
A number of hedge funds and other institutional investors have recently bought and sold shares of ORTX. Northern Trust Corp raised its holdings in Orchard Therapeutics by 10.3% during the 2nd quarter. Northern Trust Corp now owns 39,735 shares of the company’s stock worth $556,000 after buying an additional 3,695 shares during the period. BlackRock Inc. acquired a new position in shares of Orchard Therapeutics in the 2nd quarter valued at about $736,000. State Street Corp acquired a new position in shares of Orchard Therapeutics in the 3rd quarter valued at about $386,000. Point72 Asset Management L.P. acquired a new position in shares of Orchard Therapeutics in the 3rd quarter valued at about $1,915,000. Finally, Barclays PLC increased its holdings in shares of Orchard Therapeutics by 150.2% in the 3rd quarter. Barclays PLC now owns 15,427 shares of the company’s stock valued at $183,000 after purchasing an additional 9,260 shares during the period. Hedge funds and other institutional investors own 67.55% of the company’s stock.
About Orchard Therapeutics
Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration.
Featured Story: What is the significance of the death cross?
Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.